SAN DIEGO, June 12, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that its commercialization partner, Alvogen, has launched Teriparatide Injection in the United States.
Forteo (teriparatide) is a brand-name drug that doctors prescribe for some people with osteoporosis. It contains proteins that strengthen bones and stimulate new bone growth. A typical prescription is ...
July 24, 2009 — The US Food and Drug Administration (FDA) has approved an expanded indication for teriparatide (rDNA origin) injection (Forteo, Eli Lilly and Company, Inc) for the treatment of ...
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's ...
INDIANAPOLIS, May 29, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) ...
[28 June 2022 – Hong Kong] A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (the “Company”, together with its subsidiaries, the “Group”; Stock code: 00690.HK) is pleased to ...
SAN DIEGO, June 12, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that its commercialization partner, Alvogen, has launched Teriparatide Injection in the United States.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback